Car Rental Company - For Special Events, Weddings

This painting company has been stable, but they have seen sustained growth and have been one of the fastest growing small business painting companies in the Vancouver/Portland area. Starting in 2013, annual had already eclipsed half a million by 2019. With a work-from-home office, this business provides the ability to manage safely out of your own home or to be able to choose your ideal location to rent. Strong customer ratings and consistently high levels of service have made this an ideal business for anyone looking to establish a presence in the painting industry or to expand your current painting business territory and customer base. Detailed Information Employees:2 FTE Support & Training: Seller will negotiate a transition period Reason for Selling: Relocation

Our client is offering a next generation, patented medical device for the treatment of internal hemorrhoids. The procedure is painless, non-invasive, requires no anesthesia, is conducted in under 2 minutes, and can be performed in any medical setting: a doctor's office, a surgery center, an endo suite, or a hospital. Our client's product is a small, disposable, medical device that eliminates hemorrhoids. A physician uses this device by deploying a tiny rubber band on the base of the hemorrhoid. This procedure is known as rubber band ligation, and it is the #1 recommended treatment for internal hemorrhoids by the American College of Gastroenterology. Patients no longer need to use ineffective creams or receive painful, invasive surgery. Our client's device offers a permanent solution for their hemorrhoids. The device is currently manufactured in the USA through an FDA approved, ISO 13485 contract manufacturer, who specializes in medical devices. The device is sold directly to physicians of different specialties, including gastroenterologists, colorectal surgeons, GYNs, urologists and primary care physicians. The biggest targeted audience are gastroenterologists. NDA is required to secure comprehensive Confidential Information Memorandum. Growth and epansion: Nearly half of adults over the age of 50 will develop symptomatic hemorrhoids. In the U.S. alone, an estimated 60,000,000 people have experienced hemorrhoid symptom(s) at some point in their lives. Annually, over 20,000,000 people in the U.S. use an over-the-counter hemorrhoid treatment and 75% report a reoccurrence. These patients no longer need to use ineffective creams or receive painful, invasive surgery. Our client's device offers a permanent solution for their hemorrhoids. Financing is if the price and deal structure is right, and support and training is provided as required. Facilities are Outlined in CIM. Reason for selling is that the owners wish to move on to other projects.

Our client operates a lean, high-margin B2B lead-generation platform dedicated to the Internet of Things sector. By leveraging a permission-based community of over 60,000 vetted IoT decision-makers and a LinkedIn Group of 20,000+ approved professionals, they deliver turnkey sponsored webinars, white-paper campaigns, and targeted email blasts—providing technology vendors with consistently qualified leads while maintaining minimal overhead through a fully remote, contractor-driven model. NDA is required for comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.

The Company has proprietary technology that addresses a leading cause of maternal death (76,000) and fetal death (500,000) annually worldwide. 8% of pregnancies in the US and 14% worldwide have diagnoses that would be vastly improved by worldwide commercialization of the Company's proprietary device. A very low risk procedure that both provides quality of life improvement for the mother & baby and lowers health care costs is a win/win/win for all involved. Existing collaborations with major manufacturers coupled with a current expedited approval process with the FDA presents a tremendous opportunity for individuals or private equity groups seeking a transformative investment into a feel-good biotech story with exceptional legs and a vast runway with nearly unlimited upside. Able to work with groups/individuals in tranches of $500k to $1M to advance into the pilot clinical study, $2-$3MM for the pivotal clinical study towards market approval in the US. They will seek direct sales with partnered hospitals, licensing / partnership deals could utlimately yield the balance of funding to fully deploy a commercial version of the technology. NDA is required for comprehensive Confidential Information Memorandum (CIM) crafted by us. Detailed Information Competition: No current option available besides bed rest. Growth & Expansion: Huge market potential. Support & Training: Full team included. Reason for Selling: Seeking supportive capital partners to take to the next level(s). .

Patented Universal Tumor-Targeting Drug Delivery Platform Co. This pharmaceutical company has developed and patented a universal tumor-targeting drug-delivery platform that can improve the safety and efficacy of many existing chemo treatments, with the ability to target numerous different types of cancer. The technology encapsulates existing FDA-approved drugs inside lipid nanoparticles (liposomes or emulsions) coated with patented human-sourced antinuclear antibodies (ANA). The lipid nanoparticle provides long-term storage stability of the drug and controlled release of the drug over time at body-temperature, and is expected to improve the safety and efficacy profile of the drug, including passive accumulation at the tumor while not harming normal tissues. The Company's ANA, sourced from lupus patients, binds to nuclear material present in abundance in areas of necrosis (dead / ruptured cells) present in and around all solid tumors, thus anchoring the drug-filled nanoparticles at the tumor where the nanoparticle is designed to slowly release the drug directly on the tumor for more effect. As the Company's ANA is not tumor-marker specific, but rather targets necrosis present in solid tumors, the technology is designed to "universally" target many different types of cancer including breast cancer, lung, ovarian, colon, prostate, etc., as well as rare childhood cancers. The Company completed a successful proof-of-concept study at Children's Hospital using Ewing's Sarcoma transplanted in immunodeficient mice. Treatment with the Company's forumlation significantly inhibited tumor growth and extended survival times compared to control mice receiving no treatment or treatment with plain liposomal doxorubicin. The Company has been granted Orphan Drug Designation by the FDA on 2 of the lead drug formulations, providing FDA fee waivers, priority review, and 7-years exclusivity upon market approval. The orphan pathway also enables the potential for New Drug Approval after successful completion of Phase 2 studies, with Phase III data collected while in the market, thus significantly lowering the time and cost to market approval. This same drug inside the Company's tumor targeting delivery system will likely have potential to treat other pediatric cancers, and/or cancers in larger adult populations. As the Company's platform and ANA has the potential to improve the safety and efficacy of many existing FDA approved drugs or even compounds in development, the Company anticipates the potential for multiple licensing agreements with multiple pharmaceutical companies seeking to improve their existing portfolio and extend patient life as they advance into clinical stage. And as it may be possible to file for New Drug Approval following successful Phase II studies, the Company anticipates licensing potential at early clinical stage. Multiple exit opportunities exist with high impact & high ROI. The Company is seeking a supportive capital partner to maintain momentum up to $20M. Funding will be used to advance the lead drug through formal Investigational New Drug enabling studies towards New Drug Approval; estimating $3-5 Million now to advance into clinical studies. Preclinical / animal studies estimate ($3 - 5 Million and 12-18 months); follwed by potential combined Phase I-II clinical study in a rare cancer (approximately 2-3 years and $10M) to potential New Drug Approval, plus additional capital to advance additional drugs in the pipeline simultaneously, thus adding tremendous value to the Company's valuation. Valuations of pharma companies often exceed $100 Million valuation at Phase I (approx. 18 months), and New Drug Approval can exceed valuations above $1 Billion. The Company has numerous, improved high-impact cancer drugs advancing with proper support. NDA is required for comprehensive Confidential Information Memorandum crafted by ProNova Partners. Detailed Information Competition: Trying to improve existing therapies and develop novel approaches to hard to treat cancers. Growth & Expansion: Huge market potential. Financing: If the price and deal structure is right. Support & Training: Transition team included. Reason for Selling: Seeking supportive capital partners to take to the next level(s). .

As technology has become and will continue to become a driving factor within economies worldwide, the marketplace for Value Added Resellers (VARs) is growing at an astounding rate with an expected CAGR of 10% Year-over-Year through the year 2028. What makes VARs necessary within the business landscape - most large and medium-sized Companies do not order enough volume for purchasing direct from a manufacturer and can benefit from purchasing from a go-between such as a VAR, thereby creating a strong need for participants within the marketplace who function as a go-between within a B2B environment. For a VAR to maintain a livelihood and grow within this highly competitive marketplace, Resellers must have access to attractively priced goods from manufacturers, resellers, and wholesalers, and the necessary technologies to help streamline business and ensure that pricing opportunities are not overlooked (on the part of the VAR and their customer). The firms which can capture most and/or all sales within the Reseller industry will be the firms who will prevail in the years to come, ideally those who have the capability for: -Displaying a high capacity for tech solutions and customizations -An abundance of data analysis and KPIs -Sales and marketing -Quoting and sourcing -and overall Integrations and customizations Since opening its doors nearly 20 years ago this Company has created a software solution for quoting, procurement, discounting, a vast array of KPIs, and a content library that in sum is yet to be rivaled by other firms in the space. By creating the necessary relations with only the most optimal suppliers for maintaining a reputation of quality while maintaining an outstanding profit margin, it is these factors while developing strategies and sales channels that the Company has been able to boast $3MM-$4MM in gross sales in its pre-covid year. With their most recent integrations (within the last 1-2 years) the Company is NOW able to harness the expected growth within the reseller space and is expecting a massive adoption of this technology among the resellers who are aware of the demand and the impact of tech integration with these capabilities Key Investment Considerations: o Over $10M investment into the platform development, o 5000+ Tech resellers serviced, o $32B of transactions in the last 3 Years, o Presence in the US, CA, IN, SL o Full-fledged India Center with Development, QA, Marketing, and Sales team o Development team in Sri Lanka o 55%+ profitability over the last 3 years o Cloud native SaaS platform o Turnkey system and solid foundation for growth o Robust growth potential and strategies that have been clearly defined and identified by the Seller o Strong customer and referral base years of premium service offering leading reputation for quality products and pricing o 20+ years in the making o Strong process for instilling R&D and maintaining an elevated level of Quality Control o Robust and unique one-of-a-kind content library The Company and brand are very well established and only need a directed effort related to marketing and the Company can far exceed past sales levels. With proper marketing and underbidding on available contracts there are massive growth opportunities available to a new Owner. NDA is required to secure a comprehensive Confidential Information Memorandum (CIM).

This is a great chance to own a relaxed lifestyle business, helping tourists get to their luaus on time. The business has been around for 24 years, is licensed in the relevant county, and enjoys a great reputation. The current owner has elected to remain closed on Sundays, allowing for an immediate revenue increase for the motivated acquirer. While the opportunities for growth are capped geographically, the core business is very robust surviving the tourist downturn over the pandemic. There is currently demand growth on other parts of the island, for which a well-capitalized acquirer could begin servicing. The well-established drivers handle the majority of the rides, but if you enjoy chatting with people, you can always get behind the wheel yourself. Enjoy exploring the beautiful Hawaiian Island of Kauai, while on the clock! The seller has employed family in remote positions, some of whom are open to staying on, or the possibility of supplementing operations with software instead exists for an acquirer looking to improve operational efficiency. The seller is leaving the state but is open to helping an acquirer transition on their timeline. The numbers in this teaser are taken from the end of the year 2021. The Company has not maintained cash flow statements and the cash flow amount is estimated. Full access to Company financials is available with a Letter of Intent. NDA is required to receive a comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Detailed Information Facilities: Not included (their office has been run out of the family home) Competition: While ride-share apps are available on the island, scheduling consistent, reliable transportation for events, like luaus or airport trips is still commonly managed with taxi services. Growth & Expansion: The business is currently closed on Sundays, opening up operations on Sundays does provide additional revenue. Financing: TBD if structure and terms are acceptable. Support & Training: The seller wishes to provide for a successful transition of the business and is willing to provide transition support daily for up to four months. Reason for Selling: The seller is relocating to be with family and grandchildren.

The business manufactures and maintains process controllers servicing the water/wastewater, industrial, and institutional markets. Products are used in nuclear power plants, universities, hospitals, steel mills, paper mills etc. Two contract manufacturers make the products. One makes the products, assembles and drop ships them directly to customers. The other ships parts for final assembly at the Company's HQ. The business model has reduced overhead and the need for larger facilities. The Company has been through several incarnations since the late 1800's and into the1900s when early models of process controllers were invented. This legacy of innovation was nearly lost when the 2004 buyers, a private equity group, failed to implement adequate management and oversight of operations. When purchased and a new LLC established in 2019, the operation was distressed; innovation stalled and engineering on hold. The current owner, an industry-insider, knew what needed to be done, reduced manpower redundancy, but saved jobs and inspired innovation once again. The value-add potential seen in restructuring; reducing overhead, implementing operational efficiencies and improvements resulted in increased bottom-line profitability and the business' gross margin. Detailed Information Facilities: The 7,500 square foot industrial/office space rents for $4,700 per month. The lease extends through May 2024. About half of the space is open warehouse with offices around the perimeter. Competition: Three large multinational corporations are the most predominate competitors in the market that cannot compete with on price thanks to the greater flexibility in pricing. This flexibility also means the ability to offer more customization options to the customer. Other than lower price points, the Company offers great support & application-based solutions. Excellent support, outstanding products and digital marketing, have helped grow market share in since 2019. Growth & Expansion: The Company is on track for gaining market share in a variety of categories of controllers, and with the pending release of the new a next-generation controller more opportunities will open. Additionally, the Company was been awarded a contract for an international nuclear project. In the future, greater overhauls in various industries will be needed to accommodate greater automations. Many new opportunities that will originate with engineering department. The team will create drawings, and design controller configuration. Domestic and international oil and gas industry applications are still strong; natural gas pipelines require compression, measuring and refinery stations. There will be more opportunity in renewable energy, as the industry becomes more streamlined. To ensure long-range goals are reached, the Seller recommends the Buyer focus on making R&D investments, keep new product pipelines growing, and increase spending in the sales & marketing departments. Financing: TBD if structure and terms are acceptable. Support & Training: To ensure a smooth transition and ongoing success the Sellers will work with a buyer as needed for three months, and longer as a paid part-time consultant, as negotiated. Reason for Selling: Seller enjoys restructuring companies, once stabilized, it's onto the next rescue project!